EMFAT
ACAD icon

Emerald Mutual Fund Advisers Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Sell
16,576
-467,930
-97% -$11.2M 0.02% 172
2025
Q4 		$12.9M Buy
484,506
+169,182
+54% +$4.04M 0.63% 70
2025
Q3 		$6.73M Sell
315,324
-3,982
-1% -$94.2K 0.35% 99
2025
Q2 		$6.89M Sell
319,306
-175,778
-36% -$3.27M 0.42% 88
2025
Q1 		$8.22M Sell
495,084
-5,307
-1% -$96.4K 0.58% 69
2024
Q4 		$9.18M Sell
500,391
-74,419
-13% -$1.2M 0.56% 70
2024
Q3 		$8.84M Buy
574,810
+15,961
+3% +$266K 0.46% 76
2024
Q2 		$9.08M Sell
558,849
-691,380
-55% -$11.2M 0.48% 78
2024
Q1 		$23.1M Sell
1,250,229
-54,327
-4% -$1.35M 1.2% 24
2023
Q4 		$40.8M Buy
1,304,556
+568
+0% +$13.6K 2.16% 1
2023
Q3 		$27.2M Buy
1,303,988
+12,894
+1% +$350K 1.64% 9
2023
Q2 		$30.9M Buy
1,291,094
+83,792
+7% +$1.86M 1.68% 4
2023
Q1 		$22.7M Buy
1,207,302
+158,552
+15% +$3.02M 1.34% 17
2022
Q4 		$16.7M Buy
1,048,750
+16,011
+2% +$250K 1.03% 39
2022
Q3 		$16.9M Buy
1,032,739
+265,768
+35% +$4.3M 1.07% 30
2022
Q2 		$10.8M Buy
766,971
+116,978
+18% +$2.18M 0.63% 64
2022
Q1 		$15.7M Sell
649,993
-57,976
-8% -$1.4M 0.7% 57
2021
Q4 		$16.5M Buy
+707,969
New +$14.2M 0.58% 66

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's ACAD Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Acadia Pharmaceuticals (ACAD) stake by 97% in Q1 2026, selling an estimated $11.2M and leaving 16,576 shares worth $369K. The position accounts for 0.02% of the portfolio, ranked #172.

Emerald Mutual Fund Advisers Trust first reported a position in ACAD in Q4 2021 and has held it in 18 quarters since. The position peaked at $40.8M in Q4 2023. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Emerald Mutual Fund Advisers Trust held 16,576 shares of Acadia Pharmaceuticals worth $369K as of Q1 2026.
  • Emerald Mutual Fund Advisers Trust sold 467,930 Acadia Pharmaceuticals shares in Q1 2026, an estimated $11.2M.
  • Acadia Pharmaceuticals made up 0.02% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #172 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Emerald Mutual Fund Advisers Trust's Acadia Pharmaceuticals position peaked at $40.8M in Q4 2023.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.